<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991494</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-106</org_study_id>
    <secondary_id>2018-001156-36</secondary_id>
    <nct_id>NCT03991494</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Pamiparib Following Single Oral Dose Administration in Patients With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study, in participants with advanced and/or metastatic solid tumors,&#xD;
      which consists of 2 parts: a research phase (inpatient) and a treatment phase. The research&#xD;
      phase (Part 1) of the study will assess the disposition of a single oral dose of&#xD;
      [14C]-pamiparib. In the treatment phase (Part 2) participants will be allowed to have&#xD;
      continued access to pamiparib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Actual">August 5, 2020</completion_date>
  <primary_completion_date type="Actual">October 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to Infinity (AUC0-∞)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC-t)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: Maximum Observed Concentration (Cmax) of Pamiparib</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: Time of Cmax (Tmax)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Total Radioactivity Whole Blood Total Radioactivity Pharmacokinetics: Time of Cmax (Tmax)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: Apparent Total Clearance (CL/F)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pamiparib Pharmacokinetics: AUC0-∞ of Plasma Pamiparib Relative to AUC0-∞ of Plasma Total Radioactivity</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics: AUC0-∞ of Whole Blood Total Radioactivity to AUC0-∞ of Plasma Total Radioactivity</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Total Radioactivity Excreted in Urine</measure>
    <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Urinary Excretion of Pamiparib</measure>
    <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance of Pamiparib (CLR)</measure>
    <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal Recovery of Total Radioactivity</measure>
    <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Recovery of Total Radioactivity in Total Excreta</measure>
    <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events in Part1 and Part 2</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in 12-lead ECG Parameters, Vital Signs Data, Physical Examinations and Weight Data</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pamiparib Metabolite Identified and Metabolic Profile Using Measured Mass (M3)</measure>
    <time_frame>0.5, 1, 2, 6, 12, 24, 48, 72, 96, 120, and 144 hours post dose on Days 1 to 7</time_frame>
    <description>Human plasma, urine, and feces samples were analyzed by LC-MS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Pamiparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-pamiparib</intervention_name>
    <description>During the treatment phase, pamiparib 60 mg administered orally twice daily</description>
    <arm_group_label>Pamiparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically and/or cytologically confirmed advanced or metastatic solid tumor that&#xD;
             has progressed after treatment with approved therapies for which there are no standard&#xD;
             therapies available&#xD;
&#xD;
          2. A total body weight between 50 and 100 kg, inclusive at Screening&#xD;
&#xD;
          3. Measurable disease by CT/MRI&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1&#xD;
&#xD;
          5. Adequate organ function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant cardiovascular disease&#xD;
&#xD;
          2. Have a previous complete gastric resection, chronic diarrhea, active inflammatory&#xD;
             gastrointestinal disease, or any other disease causing malabsorption syndrome.&#xD;
&#xD;
          3. Poor peripheral venous access&#xD;
&#xD;
          4. Major surgical procedure, open biopsy, or significant traumatic injury ≤ 2 weeks prior&#xD;
             to Day 1, or anticipation of need for major surgical procedure during the course of&#xD;
             the study&#xD;
&#xD;
          5. Use or have anticipated need for food or drugs known to be strong or moderate CYP3A&#xD;
             inhibitors or strong CYP3A inducers&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital Clinical Research Unit</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <results_first_submitted>August 2, 2021</results_first_submitted>
  <results_first_submitted_qc>August 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2021</results_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03991494/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03991494/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study consisted of 2 parts: a Research Phase (Part 1) in which participants were inpatients and a Treatment Phase (Part 2) in which participants were outpatients.</recruitment_details>
      <pre_assignment_details>Potential participants were screened to assess their eligibility to enter the study within 28 days prior to administration of the first dose. Up to 10 participants could be enrolled to ensure that 4 participants completed Part 1 of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pamiparib</title>
          <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pamiparib</title>
          <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞)</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>hours*nanograms/milliLiter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29300" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to Infinity (AUC0-∞)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to Infinity (AUC0-∞)</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>h*ngEq/g</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42200" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32200" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t)</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29200" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC-t)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC-t)</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>h*ngEq/g</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41800" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31200" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: Maximum Observed Concentration (Cmax) of Pamiparib</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: Maximum Observed Concentration (Cmax) of Pamiparib</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2190" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Maximum Observed Concentration (Cmax)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Maximum Observed Concentration (Cmax)</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>ngEq/g</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2390" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1730" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: Time of Cmax (Tmax)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: Time of Cmax (Tmax)</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Total Radioactivity Whole Blood Total Radioactivity Pharmacokinetics: Time of Cmax (Tmax)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Total Radioactivity Whole Blood Total Radioactivity Pharmacokinetics: Time of Cmax (Tmax)</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.50" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.50" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Blood Total Radioactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: Apparent Total Clearance (CL/F)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: Apparent Total Clearance (CL/F)</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>Liters/hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: Apparent Volume of Distribution (Vz/F)</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: Apparent Volume of Distribution (Vz/F)</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pamiparib Pharmacokinetics: AUC0-∞ of Plasma Pamiparib Relative to AUC0-∞ of Plasma Total Radioactivity</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received 60 mg [14C]-pamiparib twice daily orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pamiparib Pharmacokinetics: AUC0-∞ of Plasma Pamiparib Relative to AUC0-∞ of Plasma Total Radioactivity</title>
          <population>The PK population included all participants who received at least on dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.694" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetics: AUC0-∞ of Whole Blood Total Radioactivity to AUC0-∞ of Plasma Total Radioactivity</title>
        <time_frame>Pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 6, 12, 24, 48, 72, 96, 120, and 144 hours post-dose on Day 1 to Day 7</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics: AUC0-∞ of Whole Blood Total Radioactivity to AUC0-∞ of Plasma Total Radioactivity</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.764" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Total Radioactivity Excreted in Urine</title>
        <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Radioactivity Excreted in Urine</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>% Excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.84" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Urinary Excretion of Pamiparib</title>
        <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urinary Excretion of Pamiparib</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.095" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance of Pamiparib (CLR)</title>
        <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of Pamiparib (CLR)</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>CLR (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03742" spread="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fecal Recovery of Total Radioactivity</title>
        <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Fecal Recovery of Total Radioactivity</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>% Excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.89" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Recovery of Total Radioactivity in Total Excreta</title>
        <time_frame>192 hours of [14C]-Pamiparib Administration</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally&#xD;
Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Recovery of Total Radioactivity in Total Excreta</title>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>% Excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.73" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events in Part1 and Part 2</title>
        <time_frame>Up to 6 months</time_frame>
        <population>The safety population for Part 1 consisted of all participants who received 1 dose of study drug, 60 mg [14C]-pamiparib in Part 1 and the safety population for Part 2 consisted of all participants who participated in Part 1 and received at least 1 dose of 60 mg pamiparib in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events in Part1 and Part 2</title>
          <population>The safety population for Part 1 consisted of all participants who received 1 dose of study drug, 60 mg [14C]-pamiparib in Part 1 and the safety population for Part 2 consisted of all participants who participated in Part 1 and received at least 1 dose of 60 mg pamiparib in Part 2.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 1: Number of Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 1: Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Number of Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Laboratory Abnormalities</title>
        <time_frame>Up to 6 months</time_frame>
        <population>The safety population for Part 1 consisted of all participants who received 1 dose of study drug, 60 mg [14C]-pamiparib, in Part 1 and the safety population for Part 2 consisted of all participants who participated in Part 1 and received at least 1 dose of 60 mg pamiparib in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Abnormalities</title>
          <population>The safety population for Part 1 consisted of all participants who received 1 dose of study drug, 60 mg [14C]-pamiparib, in Part 1 and the safety population for Part 2 consisted of all participants who participated in Part 1 and received at least 1 dose of 60 mg pamiparib in Part 2.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Abnormalities in 12-lead ECG Parameters, Vital Signs Data, Physical Examinations and Weight Data</title>
        <time_frame>Up to 6 months</time_frame>
        <population>The safety population for Part 1 consisted of all participants who received at least 1 dose of study drug, 60 mg [14C]-pamiparib, in Part 1 and the safety population for Part 2 consisted of all participants who participated in Part 1 and received at least 1 dose of 60 mg pamiparib in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities in 12-lead ECG Parameters, Vital Signs Data, Physical Examinations and Weight Data</title>
          <population>The safety population for Part 1 consisted of all participants who received at least 1 dose of study drug, 60 mg [14C]-pamiparib, in Part 1 and the safety population for Part 2 consisted of all participants who participated in Part 1 and received at least 1 dose of 60 mg pamiparib in Part 2.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pamiparib Metabolite Identified and Metabolic Profile Using Measured Mass (M3)</title>
        <description>Human plasma, urine, and feces samples were analyzed by LC-MS.</description>
        <time_frame>0.5, 1, 2, 6, 12, 24, 48, 72, 96, 120, and 144 hours post dose on Days 1 to 7</time_frame>
        <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pamiparib</title>
            <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received pamiparib 60 mg twice daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pamiparib Metabolite Identified and Metabolic Profile Using Measured Mass (M3)</title>
          <description>Human plasma, urine, and feces samples were analyzed by LC-MS.</description>
          <population>The PK population included all participants who received one dose of [14C]-pamiparib and had evaluable PK data.</population>
          <units>Da</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.1098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 30 days after the last dose of pamiparib - up to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pamiparib</title>
          <description>Research Phase (Part 1): participants received a single dose of 60 mg [14C]-pamiparib orally Treatment phase (Part 2): participants received 60 mg pamiparib twice daily orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information &amp; may request a further delay to protect its IP rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>BeiGene</organization>
      <phone>+1-877-828-5568</phone>
      <email>clinicaltrials@beigene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

